Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

60 Degrees Pharmaceuticals Inc (SXTP)

60 Degrees Pharmaceuticals Inc (SXTP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,895
  • Shares Outstanding, K 2,297
  • Annual Sales, $ 250 K
  • Annual Income, $ -3,770 K
  • EBIT $ -10 M
  • EBITDA $ -8 M
  • 60-Month Beta 5.36
  • Price/Sales 12.75
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.95
  • Number of Estimates 1
  • High Estimate -0.95
  • Low Estimate -0.95
  • Prior Year -5.28
  • Growth Rate Est. (year over year) +82.01%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8610 +46.34%
on 11/22/24
2.4900 -49.40%
on 12/11/24
+0.3400 (+36.96%)
since 11/20/24
3-Month
0.7015 +79.62%
on 10/30/24
2.4900 -49.40%
on 12/11/24
-0.1100 (-8.03%)
since 09/20/24
52-Week
0.7015 +79.62%
on 10/30/24
18.3600 -93.14%
on 12/26/23
-12.7800 (-91.03%)
since 12/20/23

Most Recent Stories

More News
60 Degrees Pharmaceuticals Partners with Brigham and Women's Hospital for Clinical Trial Evaluating Tafenoquine in Treatment of Severe Babesiosis

The trial evaluates tafenoquine's efficacy for severe babesiosis, led by Brigham and Women’s Hospital, involving multiple clinical sites.Quiver AI Summary60 Degrees Pharmaceuticals, Inc. has announced...

SXTP : 1.2600 (-10.64%)
60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women’s Hospital

SXTP : 1.2600 (-10.64%)
SXTPW : 0.0390 (+61.16%)
VSee Health and 60 Degrees Pharmaceuticals Interviews Aired on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FL / ACCESSWIRE / December 2, 2024 / RedChip Companies aired interviews with VSee Health, Inc. (Nasdaq:VSEE) and 60 Degrees Pharmaceuticals, Inc. (Nasdaq:SXTP) on the RedChip Small Stocks, Big...

VSEE : 1.3400 (+1.52%)
SXTP : 1.2600 (-10.64%)
60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FL / ACCESSWIRE / November 22, 2024 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc. (Nasdaq:SXTP) and Can-Fite BioPharma Ltd. (NYSE American:CANF)(TASE:CANF) on the...

SXTP : 1.2600 (-10.64%)
CANF : 1.4800 (+2.78%)
60 Degrees Pharmaceuticals Reports 164% Year-Over-Year Increase in Q3 2024 Sales Revenue

60 Degrees Pharmaceuticals reported Q3 2024 revenue of $135,000, a 164% increase, with improved gross profit and rising expenses.Quiver AI Summary60 Degrees Pharmaceuticals, Inc. reported a significant...

SXTP : 1.2600 (-10.64%)
60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results

SXTP : 1.2600 (-10.64%)
SXTPW : 0.0390 (+61.16%)
60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. Launch

SXTP : 1.2600 (-10.64%)
SXTPW : 0.0390 (+61.16%)
WallachBeth Capital Announce Closing Of 60 Degrees Pharmaceuticals IPO At $5.30 Per Unit

/PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that 60 Degrees...

SXTP : 1.2600 (-10.64%)

Business Summary

60 Degrees Pharmaceuticals Inc. specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. 60 Degrees Pharmaceuticals Inc. is based in WASHINGTON.

See More

Key Turning Points

3rd Resistance Point 1.6100
2nd Resistance Point 1.5400
1st Resistance Point 1.4000
Last Price 1.2600
1st Support Level 1.1900
2nd Support Level 1.1200
3rd Support Level 0.9800

See More

52-Week High 18.3600
Fibonacci 61.8% 11.6145
Fibonacci 50% 9.5308
Fibonacci 38.2% 7.4470
Last Price 1.2600
52-Week Low 0.7015

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar